Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Monday, April 27

Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH® Prescribing Program database (1988)

Lana Zhovtis Ryerson, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Ryan Metzger, Judith Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Zheng Ren, Christophe Hotermans, Pei-Ran Ho, Nolan Campbell
First published April 14, 2020,
Lana Zhovtis Ryerson
1Department of Neurology, NYU Langone Health, New York University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Foley
2Rocky Mountain MS Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ih Chang
3Biogen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilya Kister
1Department of Neurology, NYU Langone Health, New York University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Cutter
4University of Alabama School of Public Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Metzger
2Rocky Mountain MS Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Goldberg
5New York University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaochun Li
5New York University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan Riddle
3Biogen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Smirnakis
3Biogen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Ren
3Biogen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Hotermans
3Biogen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pei-Ran Ho
3Biogen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nolan Campbell
3Biogen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH® Prescribing Program database (1988)
Lana Zhovtis Ryerson, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Ryan Metzger, Judith Goldberg, Xiaochun Li, Evan Riddle, Karen Smirnakis, Zheng Ren, Christophe Hotermans, Pei-Ran Ho, Nolan Campbell
Neurology Apr 2020, 94 (15 Supplement) 1988;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Update the assessment of PML risk with natalizumab EID compared with Q4W dosing using TOUCH data as of June 1, 2019.

Background: Natalizumab treatment is associated with PML risk. Previous analyses of patient data in the TOUCH database have demonstrated that EID is associated with lower risk of PML than Q4W dosing.

Design/Methods: TOUCH data were used to determine whether EID is associated with lower PML risk compared with Q4W dosing in anti–JC virus antibody positive patients using 3 preplanned analyses specified for the 2017 study: a primary analysis (EID defined by the last 18 months of exposure), secondary analysis (EID defined as any prolonged period of EID in exposure history at any time), and tertiary analysis (EID defined as a dosing history consisting primarily of EID). Patients with average dosing intervals <3 or >12 weeks were excluded. Hazard ratios (HRs) of PML with EID and Q4W dosing were compared using adjusted Cox regression models and Kaplan-Meier estimates.

Results: The updated analyses included more patients than the original 2017 study (primary: 2639 EID [32.7% increase] and 15,159 Q4W [15.4% increase]; secondary: 4237 EID [27.2% increase] and 17,493 Q4W [13.4% increase]; tertiary: 1048 EID [28.6% increase] and 26,540 Q4W [14.6% increase]). For all analyses, the mean number of natalizumab infusions and mean treatment duration were greater with EID than with Q4W dosing. Average dosing intervals were unchanged from 2017. The PML HR (95% confidence interval) was 0.11 (0.05–0.28; P<0.0001) for the primary analysis and 0.20 (0.11–0.40; P<0.0001) for the secondary analysis, both favoring EID. As in previous TOUCH analyses, no EID PML cases were observed in the tertiary analysis (Kaplan-Meier log-rank test P=0.006).

Conclusions: This updated analysis of TOUCH patient data continues to demonstrate that natalizumab EID is associated with a significantly lower PML risk than Q4W dosing.

Disclosure: Dr. Zhovtis Ryerson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Zhovtis Ryerson has received personal compensation for serving on speaker bureau for Biogen, Teva, Genentech and advisory board for Biogen and Celgene. Dr. Zhovtis Ryerson has received research support from Biogen. Dr. Foley has nothing to disclose. Dr. Chang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employees of and hold stock/stock options in Biogen. Dr. Chang holds stock and/or stock options in Biogen, stock greater than 10K which sponsored research in which Dr. Chang was involved as an investigator. Dr. Kister has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Has served on advisory boards of Biogen, Genentech.Dr. Cutter has received personal compensation from AMO Pharma, Argenix, Atara Bio-therapeutics, Axon, Biogen, BioLineRx, Bio-therapeutics, Brainstorm Cell Therapeutics, Charleston Laboratories, Inc., Click Therapeutics, Genentech, Genzyme, GW Pharma, Horizon Pharmaceuticals, Klein Buendel Inc., MedDay, MedImmune, Merck, Merck/Pfizer, Neurim, Novartis OPKO Biologics, Orphazyme, Pythagoras, Inc, Reata Pharmaceuticals, Receptos/ Celgene, Sanofi- Aventis, Roche, SciFluor, Somahlution, Teva Pharma-ceuticals, TG Therapeutics, UTHealth Houston Teva Neuroscience Dr. Metzger holds stock and/or stock options in Family member owns stock in Biogen which sponsored research in which Dr. Metzger was involved as an investigator. Dr. Goldberg has nothing to disclose. Dr. Li has nothing to disclose. Dr. Riddle has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of and hold stock and/or stock options in Biogen. Dr. Riddle holds stock and/or stock options in Biogen which sponsored research in which Dr. Riddle was involved as an investigator. Dr. Smirnakis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of and hold stock and/or stock options in Biogen. Dr. Smirnakis holds stock and/or stock options in employee%20of%20and%20holds%20stock%2Fstock%20options%20in%20Biogen which sponsored research in which Dr. Smirnakis was involved as an investigator. Dr. Smirnakis holds stock and/or stock options in employee%20of%20and%20holds%20stock%2Fstock%20options%20in%20Biogen. Dr. Ren has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of and hold stock and/or stock options in Biogen. Dr. Hotermans has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Hotermans holds stock and/or stock options in Biogen which sponsored research in which Dr. Hotermans was involved as an investigator.Dr. Ho has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Ho holds stock and/or stock options in Biogen.Dr. Campbell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Biogen. Dr. Campbell has received compensation for serving on the Board of Directors of Received stock as employee of Biogen. Dr. Campbell holds stock and/or stock options in Biogen.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise